Global CGRP Inhibitor 麻豆原创 Research Report 2025

Publication ID:

PB504257741

Publication Date:

May 2, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for CGRP Inhibitor was valued at US$ 3157 million in the year 2024 and is projected to reach a revised size of US$ 4593 million by 2031, growing at a CAGR of 5.6% during the forecast period.
CGRP inhibitors are a class of medications that block the activity of calcitonin gene-related peptide (CGRP), a neuropeptide involved in the pathophysiology of migraines. By targeting either the CGRP ligand or its receptor, these drugs prevent the dilation of blood vessels and inflammation associated with migraine attacks. CGRP inhibitors are used primarily for the prevention and acute treatment of migraines and include monoclonal antibodies (e.g., erenumab, fremanezumab, galcanezumab) and small molecule receptor antagonists (gepants). They are generally well tolerated and represent a significant advancement in migraine therapy.
North American market for CGRP Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for CGRP Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for CGRP Inhibitor in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of CGRP Inhibitor include AbbVie, Amgen, Eli Lilly, Teva Pharmaceutical, Pfizer, Lundbeck, Novartis, Bristol Myers Squibb, Satsuma, Zosano Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CGRP Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CGRP Inhibitor.
The CGRP Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CGRP Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CGRP Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
AbbVie
Amgen
Eli Lilly
Teva Pharmaceutical
Pfizer
Lundbeck
Novartis
Bristol Myers Squibb
Satsuma
Zosano Pharma
Dr.Reddy鈥檚 Laboratories
Segment by Type
Infusions
Oral
Other
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CGRP Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global CGRP Inhibitor 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Infusions
1.2.3 Oral
1.2.4 Other
1.3 麻豆原创 by Application
1.3.1 Global CGRP Inhibitor 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CGRP Inhibitor 麻豆原创 Perspective (2020-2031)
2.2 Global CGRP Inhibitor Growth Trends by Region
2.2.1 Global CGRP Inhibitor 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 CGRP Inhibitor Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 CGRP Inhibitor Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 CGRP Inhibitor 麻豆原创 Dynamics
2.3.1 CGRP Inhibitor Industry Trends
2.3.2 CGRP Inhibitor 麻豆原创 Drivers
2.3.3 CGRP Inhibitor 麻豆原创 Challenges
2.3.4 CGRP Inhibitor 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top CGRP Inhibitor Players by Revenue
3.1.1 Global Top CGRP Inhibitor Players by Revenue (2020-2025)
3.1.2 Global CGRP Inhibitor Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Top CGRP Inhibitor Players by Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by CGRP Inhibitor Revenue
3.4 Global CGRP Inhibitor 麻豆原创 Concentration Ratio
3.4.1 Global CGRP Inhibitor 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CGRP Inhibitor Revenue in 2024
3.5 Global Key Players of CGRP Inhibitor Head office and Area Served
3.6 Global Key Players of CGRP Inhibitor, Product and Application
3.7 Global Key Players of CGRP Inhibitor, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CGRP Inhibitor Breakdown Data by Type
4.1 Global CGRP Inhibitor Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global CGRP Inhibitor Forecasted 麻豆原创 Size by Type (2026-2031)
5 CGRP Inhibitor Breakdown Data by Application
5.1 Global CGRP Inhibitor Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global CGRP Inhibitor Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America CGRP Inhibitor 麻豆原创 Size (2020-2031)
6.2 North America CGRP Inhibitor 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America CGRP Inhibitor 麻豆原创 Size by Country (2020-2025)
6.4 North America CGRP Inhibitor 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CGRP Inhibitor 麻豆原创 Size (2020-2031)
7.2 Europe CGRP Inhibitor 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe CGRP Inhibitor 麻豆原创 Size by Country (2020-2025)
7.4 Europe CGRP Inhibitor 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CGRP Inhibitor 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific CGRP Inhibitor 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific CGRP Inhibitor 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific CGRP Inhibitor 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CGRP Inhibitor 麻豆原创 Size (2020-2031)
9.2 Latin America CGRP Inhibitor 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America CGRP Inhibitor 麻豆原创 Size by Country (2020-2025)
9.4 Latin America CGRP Inhibitor 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CGRP Inhibitor 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa CGRP Inhibitor 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa CGRP Inhibitor 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa CGRP Inhibitor 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie CGRP Inhibitor Introduction
11.1.4 AbbVie Revenue in CGRP Inhibitor Business (2020-2025)
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen CGRP Inhibitor Introduction
11.2.4 Amgen Revenue in CGRP Inhibitor Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly CGRP Inhibitor Introduction
11.3.4 Eli Lilly Revenue in CGRP Inhibitor Business (2020-2025)
11.3.5 Eli Lilly Recent Development
11.4 Teva Pharmaceutical
11.4.1 Teva Pharmaceutical Company Details
11.4.2 Teva Pharmaceutical Business Overview
11.4.3 Teva Pharmaceutical CGRP Inhibitor Introduction
11.4.4 Teva Pharmaceutical Revenue in CGRP Inhibitor Business (2020-2025)
11.4.5 Teva Pharmaceutical Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer CGRP Inhibitor Introduction
11.5.4 Pfizer Revenue in CGRP Inhibitor Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 Lundbeck
11.6.1 Lundbeck Company Details
11.6.2 Lundbeck Business Overview
11.6.3 Lundbeck CGRP Inhibitor Introduction
11.6.4 Lundbeck Revenue in CGRP Inhibitor Business (2020-2025)
11.6.5 Lundbeck Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis CGRP Inhibitor Introduction
11.7.4 Novartis Revenue in CGRP Inhibitor Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Company Details
11.8.2 Bristol Myers Squibb Business Overview
11.8.3 Bristol Myers Squibb CGRP Inhibitor Introduction
11.8.4 Bristol Myers Squibb Revenue in CGRP Inhibitor Business (2020-2025)
11.8.5 Bristol Myers Squibb Recent Development
11.9 Satsuma
11.9.1 Satsuma Company Details
11.9.2 Satsuma Business Overview
11.9.3 Satsuma CGRP Inhibitor Introduction
11.9.4 Satsuma Revenue in CGRP Inhibitor Business (2020-2025)
11.9.5 Satsuma Recent Development
11.10 Zosano Pharma
11.10.1 Zosano Pharma Company Details
11.10.2 Zosano Pharma Business Overview
11.10.3 Zosano Pharma CGRP Inhibitor Introduction
11.10.4 Zosano Pharma Revenue in CGRP Inhibitor Business (2020-2025)
11.10.5 Zosano Pharma Recent Development
11.11 Dr.Reddy鈥檚 Laboratories
11.11.1 Dr.Reddy鈥檚 Laboratories Company Details
11.11.2 Dr.Reddy鈥檚 Laboratories Business Overview
11.11.3 Dr.Reddy鈥檚 Laboratories CGRP Inhibitor Introduction
11.11.4 Dr.Reddy鈥檚 Laboratories Revenue in CGRP Inhibitor Business (2020-2025)
11.11.5 Dr.Reddy鈥檚 Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

AbbVie
Amgen
Eli Lilly
Teva Pharmaceutical
Pfizer
Lundbeck
Novartis
Bristol Myers Squibb
Satsuma
Zosano Pharma
Dr.Reddy鈥檚 Laboratories

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.